[Federal Register Volume 63, Number 77 (Wednesday, April 22, 1998)]
[Notices]
[Pages 19921-19922]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-10575]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has made a final finding of scientific misconduct in the 
following case:

Patrina Lowe, Bienville Medical Group

    Based on an investigation conducted by ORI's Division of Research 
Investigations, ORI found that Ms. Lowe, former staff member, Bienville 
Medical Group, engaged in scientific misconduct in clinical research 
conducted as part of a multicenter clinical trial supported by a 
National Heart, Lung, and Blood Institute (NHLBI), National Institutes 
of Health (NIH) contract. Ms. Lowe falsified and/or fabricated data and 
information collected from patients for the Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) at the 
clinical site in Terry, Mississippi. ORI acknowledges Ms.

[[Page 19922]]

Lowe's cooperation and assistance in completing its investigation.
    Ms. Lowe has accepted the ORI finding and has entered into an 
Agreement with ORI in which she has voluntarily agreed, for the three 
(3) year period beginning April 6, 1998:
    (1) To exclude herself from serving in any advisory capacity to the 
Public Health Service (PHS), including but not limited to service on 
any PHS advisory committee, board, and/or peer review committee, or as 
a consultant; and
    (2) That any institution that submits an application for PHS 
support for a research project on which Ms. Lowe's participation is 
proposed or which uses her in any capacity on PHS supported research or 
that submits a report of PHS-funded research in which she is involved 
must concurrently submit a plan for supervision of her duties to the 
funding agency for approval. The supervisory plan must be designed to 
ensure the scientific integrity of Ms. Lowe's research contribution. 
The institution also must submit a copy of the supervisory plan to ORI.
    No scientific publications were required to be corrected as part of 
this Agreement.

FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Research 
Investigations, Office of Research Integrity, 5515 Security Lane, Suite 
700, Rockville, MD 20852, (301) 443-5330.
Chris B. Pascal,
Acting Director, Office of Research Integrity.
[FR Doc. 98-10575 Filed 4-21-98; 8:45 am]
BILLING CODE 4160-17-P